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Summary 
Serum mannose-binding protein (MBP) is a C-type lectin that binds to terminal mannose and 
N-acetylglucosamine moieties present on surfaces of certain pathogens and activates the classical 
complement pathway. In the present study, we describe the mechanism underlying the activation 
triggered by  MBP.  The  human  serum  MBP  fraction  was  obtained by  sequential  af~nity 
chromatography  on mannan-Sepharose, anti-IgM-Sepharose and anti-MBP-Sepharose in the presence 
of calcium ions. This fraction contained a Cls-like serine protease as assessed by C4 consumption. 
The Cls-like serine protease, designated MBP-associated serine protease (MASP), was separated 
from MBP by rechromatography on anti-MBP-Sepharose  in the presence of ethylenediaminetetra- 
acetic acid. MASP exhibited both C4- and C2-consuming activities. The molecular mass of MASP 
was estimated to be 83 kD with two polypeptides of heavy (66 kD) and light (L) (31 kD) chains 
linked by disulfide bonds. The serine residue responsible for protease activity is located on the 
L chain. Reconstitution experiments using MASP and MBP revealed that combination of the 
two components  restores C4- and C2-activating capacity on mannan. Based on analyses of mdecular 
size, antigenicity, and 11 NH2-terminal amino acid sequences of the L chain, we conclude that 
MASP is a novel protein different from Clr or Cls. Our findings are not in accord with a proposed 
mechanism by which MBP utilizes the Clr2-Cls2 complex to initiate the classical complement 
pathway. 
S 
erum mannose-binding protein (MBP) 1 is a C-type lectin 
(1) which binds in the presence of calcium ions to man- 
nose and N-acetylglucosamine present on yeast cell walls, 
gram-negative bacteria,  or other ceils. MBP has been docu- 
mented in human (2), rabbit (3), rat (4), and bovine (5) sera, 
and its apparent molecular mass is about 400-700 kD with 
a subunit of about 32 kD. Each subunit has a collagenous 
and a carbohydrate-recognizing region (6, 7). MBP is thought 
to play a crucial role in host defense against certain pathogens 
containing mannose or N-acetylglucosamine on their sur- 
faces. Several lines of evidence show that MBP functions as 
an opsonin. Kuhlman et al. (8) reported that on binding to 
Salmonella montevideo bearing a mannose-rich LPS, MBP en- 
hances killing by phagocytes. Low levels of MBP in the human 
serum have been shown to be linked to a defect in opsoniza- 
1 Abbreviations used in this paper: DFP, diisopropylfluorophosphate; EA, 
sheep etythrocytes sensitized with antibody; EAC14, EA bearing guinea 
pig CI and human C4b; EDTA-GVB, gelatin Veronal buffer containing 
EDTA; E.mannan, sheep erythrocytes coated with yeast mannan; MASP, 
MBP-associated serine protease; MBP, mannose-binding protein; MGVB, 
gehtin Veronal buffer containing mannitol, CaC12 and MgCh; ,v-APMSF, 
(/,-amidinophenyl)raethanesulfonylfluoride;  RaRF, Ra-reactive  factor; SFU, 
site-forming unit;  VB, Veronal buffer. 
tion of bakers' yeast (Saccharomyces cerevisiae) (9). MBP shows 
structural similarity to Clq, a subcomponent of the first com- 
plement component (C1), and can bind to the Clq receptor 
thereby enhancing phagocytosis (10). MBP also inhibits HW 
infection of ceUs by binding to gp120, which possesses a high 
mannose oligosaccharide  (11, 12). Further, MBP is able to 
trigger complement activation through both the classical (13, 
14) and alternative (15) pathways upon binding to pathogens 
possessing mannose, leading to direct killing. Complement 
activation initiated by MBP generates C3b or iC3b, both of 
which act  as opsonins (16). 
The mechanism by  which MBP  activates  the classical 
pathway has been reported by two groups (17, 18) which 
reached the same conclusion that MBP, like Clq, can associate 
with the unactivated proenzyme Clr2-Clsz complex so that 
the classical pathway proceeds upon binding to mannan. This 
is based on the finding that isolated MBP and the Clr2-Cls2 
proenzyme forms a complex, resulting in activation of Cls. 
These facts imply that MBP might utilize Clr and Cls for 
activation in vivo. However,  an alternate mechanism is that 
protease(s) other than Clr and Cls may interact with MBP 
and initiate the classical pathway. In this study, we obtained 
human serum MBP in association with a Cls-like serine pro- 
tease which consumes C4 and C2, resuhing in complement 
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tion of the Cls-like serine protease. 
Materials and Methods 
Reagents.  Mannan from S. cerevisiae was purchased from Sigma 
Chemical Co. (St. Louis, MO). (p-amidinophenyl)methanesulfonyl- 
fluoride ~-APMSF), mannose, and tannic acid were from Wako 
Pure Chemical  Industries (Osaka,  Japan). CNBr-activated  Sepharose 
4B was from Pharmacia Fine Chemicals (Uppsala, Sweden). Poly- 
donal anti-human Cls serum (rabbit) was from Behringwerke AB 
(Marburg, Germany). Monoclonal anti-human IgM was prepared 
in our laboratory, Monoclonal anti-MBP (3E7) was obtained as 
previously described (19). Coupling of mannan, anti-IgM, or anti- 
MBP to CNBr-activated Sepharose 4B was performed according 
to the manufacturer's instructions. Diisopropylfluorophosphate, 
[1,3-3H] (3H-DFP) and [mI]NaI were purchased from New En- 
gland Nuclear (Boston, MA). C4 was labeled using [12SI]NaI and 
Iodo-Gen from Pierce Chemical Co. (Rockford, IL), according to 
the manufacturer's  instructions. Human Cls (20), C4 (21), C2 (22), 
and oxidized C2  (~  (23) were prepared as described previ- 
ously. Guinea pig C1 was purchased from Diamedix Corporation 
(Miami, FL). Veronal  buffered saline (VB) was a standard solution 
of  Veronal buffer containing 0.148 M NaC1 (pH 7.4). EDTA-GVB 
was VB supplemented with 10 mM EDTA and 0.1% gelatin. 
MGVB was low ionic strength Veronal buffered saline containing 
0.1% gdatin, 2.3% mannitol, 2 mM CaCI~ and 0.5 mM MgClz. 
Purification of MBP and MASP.  Human serum obtained by 
recalcification of outdated human citrated plasma. Polyethylene 
glycol 4,000 at a concentration of 7% was added and precipitate 
dissolved in 50 mM Tris-HC1, 1 M NaC1, 50 mM CaCI2, pH 7.8 
(starting buffer), and applied to a yeast mannan-Sepharose  column. 
After washing the column, MBP was eluted with starting buffer 
containing 300 mM mannose. The eluate was contaminated with 
IgM and IgG. To remove IgM, the eluted fractions were passed 
through a monoclonal anti-human IgM-Sepharose column. The 
pass-through fractions  were then applied to a monoclonal  anti-MBP 
(3ET)-Sepharose column and duted with 0.1 M glycine-HC1,  pH 
2.2. After concentration with a YM 10 membrane (Amicon Corp., 
Danvers, MA), the MBP pool from the 3ET-Sepharose column was 
dialyzed against 50 mM Tris-HC1, 1 M NaC1, 20 mM EDTA, pH 
7.8 and applied to a second 3E7-Sepharose column.  The pass- 
through fractions containing MASP were collected and MBP was 
eluted with 0.1 M glycine-HC1, pH 2.2. 
C4 or C2 Consumption.  C4 or C2 (2 site-forming units [SFU]) 
was incubated at 37~  for 30 win with an equal volume of sample 
or MGVB. For C4, the reaction mixtures (100 #1) were further 
incubated for 60 min with 100/~1 of C4-deficient  guinea pig serum 
and  100  /~1  of  sheep erythrocytes  sensitized with  Ab  (EA) 
(10S/ml), followed by addition of I ml of EDTA-GVB. The OD 
of the supernatant was determined at 414 nm. The percentage of 
C4 consumption was calculated from the hemolytic rate (2')" For 
C2 consumption, mixtures of C2 and sample were allowed  to react 
with EAC14  cells  at 30~  for 5 min, foUowed  by addition of  guinea 
pig serum diluted 1:20 with EDTA-GVB. Incubation was then con- 
tinued at 37~  for an additional 60 win. Subsequent procedures 
were the same as in the C4 consumption assay. 
C4-andC2-activatingCapacityonE.mannan.  Sheep  erythrocytes 
(5  x  10S/m1) suspended in PBS were incubated at 37~  for 15 
win with an equal volume of tannic acid (0.125 mg/ml). The cells 
were washed and then incubated with an equal volume of yeast 
mannan (20 mg/ml) at 37~  for 60 rain. After centrifugation, 
E.mannan were washed with MGVB and suspended at 10S/ml. 
For assay  of C4- and C2-activating capacity on E.mannan, 100 ~1 
of sample were incubated with an equal volume of E.mannan 
(10S/ml) at 30~  for 30 min. After washing, the cells were in- 
cubated at 30~  for 20 win with 50/~1 of human C4 and ~ 
(20 SFU each). The mixtures were further incubated at 37~  for 
60 rain with 200 #1 of guinea pig serum diluted 1:20 with EDTA- 
GVB. After adding 1 ml of EDTA-GVB, the hemolytic rate (y) 
was calculated spectrophotometfically. The average number  of 
hemolytic sites per ceU (z) was calculated as z  =  -In (l-y). 
SDS-PAGE and Western Blotting.  SDS-PAGE  was performed 
using the Laemmli system (24). Western blotting was performed 
as previously  described (25) except that an Immobilon-P membrane 
(MiUipore Corp., Bedford, MA) was used. 
Cleavage of c4.  MASP  (100 ng) or Cls (100 ng) in 10 #1 of 
VB was incubated with 10/~1 of 12sI-C4 (260,000 cpm/50 ng C4) 
at 37~  for 60 min and subjected to SDS-PAGE followed  by auto- 
radiography. 
~H-DFP Labeling.  20/~1 of 3H-DFP (740 kBq) were incubated 
with 200/~I of MASP or Cls at 4~  for 17 h. 40/~1 of BSA (1.6 
mg/ml) was added to the reaction mixture as a carrier, and the 
proteins were then precipitated by the addition of 1 ml of chilled 
acetone, and kept at -200C for 2 h. After centrifugation at 15,000 
rpm for 10 win, the precipitates were dissolved  in SDS-PAGE  buffer. 
After SDS-PAGE, fluorography was carried out at  -80~ 
Amino Acid Sequence Analysis.  MASP  was subjected to SDS- 
PAGE under reducing conditions and transferred to a PVDF mem- 
brane (Bio-Rad Laboratories, Richmond, CA). After staining with 
Coomassie brilliant blue, the band was excised and subjected to 
gas-phase protein sequencing (Shimadzu PSQ-1; Shimadzu Cor- 
poration, Kyoto, Japan). 
Results 
Cls-like Serine Protease Activities in the MBP Fraction.  To 
examine whether MBP contains a protease responsible for 
activation of the classical complement pathway upon binding 
to mannan such as Clr2-Cls2, we assumed that an associa- 
tion between MBP and such a protease is facilitated by the 
presence of calcium ions, as is the case with the C1 complex. 
Accordingly, instead of EDTA, which is commonly used, we 
chose mannose for duting MBP to keep the complex intact 
while eluting from mannan-Sepharose column after adsorp- 
tion. Because the MBP fraction from a mannan-Sepharose 
contained IgM and IgG as contaminants, it was first passed 
through a monoclonal anti-IgM-Sepharose column. We then 
used monoclonal anti-MBP antibody (3E7)-coupled-Sepharose 
to remove IgG. MBP was duted with an acidic buffer from 
a 3E7-Sepharose  column. To test the MBP fraction for C4- 
and C2-activating capacity, E.mannan were sensitized with 
the MBP fraction from 3E7-Sepharose  and incubated with 
human C4 and C2 followed  by guinea pig complement diluted 
with EDTA-containing buffer as a source of C3-C9. As shown 
in Fig.  1 A, the extent of hemolysis of E.mannan depended 
on the amount of the MSP fraction added, which indicated 
that the fraction contained a Cls-like protease which acti- 
vates C4 and C2, generating C3 convertase of the classical 
pathway. Hemolysis was completely impaired when the MBP 
fraction was preincubated with E.mannan in the presence of 
p-APMSF (data not shown). These results indicate that the 
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Figure 1.  Cls-like protease activities  of the MBP fraction  from anti- 
MBP (3E7)-Sepharose.  (A) C4- and C2-activation  on mannan. E.mannan 
sensitized with the indicated amounts of the MBP fraction from 3E7- 
Sepharose was treated  with C4 and ~  and subsequently  with C3-C9. 
The extent of hemolysis  is expressed  as the z value. (B) C4 consumption. 
C4 was incubated  with the indicated  amounts of the MBP fraction  from 
3E7-Sepharose. Residual C4 activity  was determined  using C4-defident 
guinea pig serum and EA. 
protease in the MBP fraction responsible for activation of C4 
and C2 belongs to the serine protease family. The MBP frac- 
tion from 3E7-Sepharose was tested for C4-consuming ac- 
tivity and found to exhibit activity similar to Cls as shown 
in Fig.  1 B. 
Isolation of  a Cls-like Serine Protease in the MBP Fraction.  To 
separate the Cls-like serine protease(s) from MBP, the MBP 
fraction from a 3E7-Sepharose column was dialyzed against 
buffer containing EDTA and rechromatographed on a 3E7- 
Sepharose column. C4-consuming activity was recovered in 
the pass-through, whereas MBP was retained on the column 
and eluted with an acidic buffer (Fig. 2). C4- and C2-activating 
capacity, which results in generation of C3 convertase on 
E.mannan, was not observed either in the pass-through frac- 
tion or in  the eluate obtained with the acidic  buffer. 
The SDS-PAGE profile of the Cls-like serine protease in 
the pass-through which displays  C4-consuming activity is 
shown in Fig.  2.  The protease appears under nonreducing 
conditions as a single band with a molecular mass of 83 kD. 
We  designate  this  protein MBP-associated serine protease 
(MASP). Under reducing conditions, MASP shows two bands 
corresponding to 66 and 31 kD (tentatively termed as H chain 
for the 66 kD component and L chain for the 31 kD com- 
ponent). 
Comparison  of  MASP with CIs.  To examine the possibility 
that MASP is Cls, we compared their behavior on SDS-PAGE. 
As shown in Fig. 3 A, although the apparent molecular weight 
of MASP is slightly larger than that of Cls under nonreducing 
conditions, both H  and L chains of MASP migrated faster 
than the two corresponding chains of Cls under reducing 
conditions. 
Cls is a serine protease whose L chain was labeled with 
3H-DFP.  3H-DFP was also found to be incorporated into the 
L chain of MASP, indicating that its active site is located on 
the L  chain (Fig.  3 B). 
To compare antigenicities of MASP and Cls, we performed 
Western blot analysis using polyclonal anti-Cls serum. MASP 
at  a  100-fold higher concentration than Cls did not react 
with polyclonal anti-Cls under conditions in which Cls was 
detected at concentrations as low as 1/~g/ml (data not shown). 
Properties of  MASP.  We then examined whether anti-Cls 
serum inhibits C4 consumption by MASP. Under conditions 
in which MASP and Cls exhibit the same C4-consuming 
activities, MASP or Cls was incubated with C4 in the pres- 
Figure 2.  Separation  of  MASP from  MBP by rechromatography  on 3E7- 
Sepharose. Fractions  from  anti-IgM-Sepharose  we~ dialyzed  against EDTA- 
containing  buffer  and chromatographed  on a second  3E7-Sepharose  column. 
Fractions were diluted 1/500 for the C4 consumption  assay. (Inset) SDS- 
PAGE analysis of MASP and MBP. MASP (fractions  2-9, lane  a,) or MBP 
(fractions 22-29, lane b) was subjected  to SDS-PAGE  (8% gd) under re- 
ducing (left)  or nonreducing  (right) conditions.  Proteins  were  stained  with 
Coomassie brilliant blue R-250. 
Figure 3.  Comparison  between MASP and Cls. (A) SDS-PAGE  anal- 
ysis MASP (lane  a) or Cls (lane b) was subjected to SDS-PAGE  (8% gd) 
under reducing (/eft) or nonreducing (right) conditions.  Proteins  were  stained 
with Coomassie  brilliant blue IL-250. (B) 3H-DFP  hbding. After  labeling 
with 3H-DFP as described  in Materials and Methods, MASP (lane a) or 
Cls (lane b) was subjected to SDS-PAGE under reducing (left) or non- 
redudng (right) conditions, followed  by autoradiography. 
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anti-Cls  on  C4  consumption  mediated  by 
MASP or Cls. MASP (O) or Cls (0) was in- 
cubated  with C4 in the presence of the indi- 
cated  amounts  of heat-inactivated  anti-Cls 
serum at 370C for 30 rain and residual C4 ac- 
tivity was determined.  (B) Cleavage of C4 by 
MASP.  t2sI-C4 was  incubated  with  MASP 
(lane a), buffer (lane b), or Cls (lane c) at 370C 
for 60 rain and subjected to SDS-PAGE (7.5% 
gel) followed by autoradiography. (C) C2 con- 
sumption by MASP. Human C2 was incubated 
with the indicated amounts of MASP at 37~ 
for 30 rain and  residual C2 activity was de- 
termined. 
ence or absence of anti-Cls serum,  and residual C4 activity 
was assayed. As shown in Fig. 4 A, C4 consumption by Cls 
was inhibited up to 100% by anti-Cls serum.  On the other 
hand,  anti-Cls serum did not inhibit  C4 consumption by 
MASP, indicating  that Cls is not involved in C4 consump- 
tion mediated by MASP. 
In experiments  shown in Fig. 4 B, we examined cleavage 
of C4 by MASP. Radiolabeled C4 was incubated with M_ASP 
and  subjected  to SDS-PAGE and radioautograpby.  C4 was 
cleaved by MASP generating a fragment corresponding to 
C4b with appearance of the or' chain. 
By analogy to Cls, M_ASP  was expected to have both C2- 
and  C4-consuming activities.  C2 was incubated  with var- 
ious amounts of MASP and residual C2 activity was deter- 
mined. As shown in Fig. 4 C, C2 was consumed by MASP 
in a dose-dependent manner. Furthermore,  we compared C4- 
or C2-consuming activities  of MASP and  Cls,  and  found 
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Figure 5.  Rcconstitution of MASP and MBP for exhibiting C4 and 
C2- activating capacity on mannan.  100/~1 of E.mannan  (10S/ml), 50/~1 
of MBP (800 ng/ml), and 50 #1 of M_ASP (600, 120, 24 ng/ml) were in- 
cubated  at 30~  for 30 rain. As a control, MBP alone or MASP alone 
(600  ng/ml) was  incubated  with  E.mannan.  After centrifugation and 
washing,  the cells were suspended in MGVB at 10S/ml. C4 and C2 acti- 
vation on E.mannan was assayed as described in Materials and Methods. 
that Cls displays  about 150-fold higher C4- or C2-consuming 
activity than does M.ASP on a molar basis (data not shown). 
Reconstitution of  C4- and C2.activating Capacity  on E.mannan. 
As described above, MASP and MBP were separated by an 
affinity chromatography on a second 3E7-Sepharose column 
in the presence of  EDTA, and C4- and C2-activating capacity 
was not found in either fraction. Accordingly, we conducted 
a reconstitution  experiment involving a hemolytic assay  using 
isolated M.ASP and MBP, as shown in Fig.  1, to determine 
if recombination of MASP and MBP could restore C4- and 
C2-activating  capacity  on  E.mannan.  Preincubation  of 
E.mannan  with MBP or MASP alone did not result in lysis. 
When MBP and MASP were simultaneously  prdncubated 
with E.mannan,  hemolysis was noted and its rate increased, 
relative to the amount of MASP used with a fixed concentra- 
tion of MBP (Fig. 5). These results indicate that MBP and 
MASP can associate to exhibit C4- and C2-activating capacity 
on mannan. 
NH2-Terminal Amino Acid Sequence of MASP.  The  11 
NHz-terminal amino acid sequence of the MASP L chain 
was determined  (Fig. 6). For comparison,  the NH2-terminal 
amino acid sequences (26) of the L chains of human Cls and 
Clr are aligned.  It is clear that MASP is different from Cls 
or Clr, although it shows some homology with these subunits. 
We conducted protein database searches in GenBank (release 
72) and found that MASP is a novel protein that has as yet 
not been reported. 
Discussion 
In  reconstitution  experiments  using  MBP  and  the 
Clr2-Cls2 complex,  Ohta et al. (17) and Lu et al. (18) con- 
1  2  3  4  5  6  7  8  9  10  II 
MASP  :  ~-Phe-Asn~-~Arg-  X  -~-~-Gln-Lys-~Thr 
Human Cls  [I  I  e~I  le-Gly-~ly~Ser-Asp~Ala~Asp-I  le-  yL~-Asn 
Human Clr: I1~_~bIle-Gly-~-Gln-Lys-[%_~Lys-Met-~__~Asn 
Fignre 6.  NH2-terminal amino add sequences of the L chains of MASP, 
human Cls, and Clr. Sequences of the L chains of human Cls and Clr 
have been reported (26). (Boxed) Amino acids common to sequences of 
MASP and  the other two proteases. 
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with  the unactivated  proenzyme complex Clr2-Cls2,  re- 
sulting in activation of Cls when MBP binds to mannan. 
If  classical complement pathway activation triggered by MBP 
occurs in serum by this mechanism,  one would expect the 
activated Cls in the MBP fraction obtained from a mannan- 
Sepharose column after dution with mannose. Our attempt 
to isolate the activated Cls from the MBP fraction revealed 
a Cls-like serine protease with both C4- and C2-consuming 
activity associated with MBP. We isolated and characterized 
this Cls-like serine protease termed MASP and found that 
it consisted of two polypeptides linked by disulfide bond(s), 
and that the active site for the serine protease is located on 
the L  chain.  Structurally and functionally,  its  properties 
resemble those of Cls. We concluded, however, that MASP 
is a novel serine protease, involved in classical complement 
pathway activation. We based this on the following consider- 
ations. First,  the molecular size of MASP is different from 
that of Cls, as judged by results from SDS-PAGE. Under 
nonreducing conditions,  the apparent molecular weight of 
MASP is slightly larger than that of Cls. Under reducing 
conditions, the two MASP polypeptides are smaller than the 
corresponding Cls polypeptides. These discrepandes are prob- 
ably  due to  intradisulfide  bonds  within  their  molecules. 
Second, polyclonal antibodies against Cls did not react with 
MASP as assessed by immunoblotting, indicating that these 
two proteases are antigenically  distinct. Third, providing more 
direct evidence, the NHz-terminal amino acid sequences of 
the L chains of MASP and Cls differ. Amino acid analysis 
also showed that MASP is different from Clr. It is unlikely 
that both Cls and MASP are involved in classical pathway 
activation initiated by MBP, because anti-Cls serum did not 
inhibit C4 consumption by the MASP fraction. 
Ra-reactive factors (RaRF) are complement-dependent bac- 
tericidal substances  found in the sera of  vertebrates (27), which 
recognize and bind to mannose and N-acetylglucosamine  in 
the Ra chemotype strain of Salmonella typhimurium in the pres- 
ence of calcium ions. Mouse RaRF has been most character- 
ized (28-30) and was found to consist of at least two compo- 
nents:  a carbohydrate-binding  component and a C4-  and 
C2-consuming component. The former component (P28a 
and P28b) shares structural properties with MBP (31), and 
the latter is a protease that displays a Cls-like activity in the 
classical pathway activation by RaRF (32, 33). We recently 
demonstrated that human MBP is a component of RaRF (19). 
Taken together, our findings indicate that like mouse RaRF, 
human RaR.F consists of a carbohydrate-binding component 
(i.e., MBP) and a Cls-like serine protease (i.e., MASP). 
Classical complement pathway activation initiated by Clq 
requires Clr as welt as Cls. If a Clr-like serine protease is 
involved in the activation triggered by MBP, this protease 
should  have coeluted with MASP  from the second 3E7- 
Sepharose column. However, the MASP preparation contained 
no Clr-like serine protease as determined  by SDS-PAGE anal- 
ysis. In addition,  the results of reconstitution experiments 
using MBP and MASP suggest no requirement for a Clr- 
like serine protease for dassical pathway activation initiated 
by MaP. 
By analogy to Cls (34), it is conceivable that MASP also 
has an unactivated proenzyme form with a single polypep- 
tide in association with MBP in the presence of  calcium ions, 
and that MASP changes from the unactivated  to activated 
form, accompanied by a cleavage of the single polypeptide 
into two chains linked by disulfide bond(s) when MBP binds 
to mannan. We can assume that upon activation, MASP un- 
dergoes conformational changes, thereby acquiring autoacti- 
vation capacity like that of Clr.  If this is the case, MASP 
may be unique in exhibiting both Clr- and Cls-like activities. 
In conclusion, we have isolated and characterized a novel 
Cls-like serine protease termed MASP which can initiate the 
classical complement pathway in association with MBP on 
mannan. Our findings are not in accord with a proposed mech- 
anism by which MBP utilizes the Clr2-Cls2 complex to ini- 
tiate the activation. 
The authors thank Dr. Akihiko Tsuchiya  (Kyowa  Hakko Kogyo Co., Ltd., Mishima, Japan) for amino 
acid analysis; Dr. William Campbell (Nagoya  City University,  Nagoya,  Japan) for English editing; Ms. 
Mihoko Mogi for technical assistance; and Ms. Takako Sugiyama  for preparation of the manuscript. 
This work was supported  in part by a grant from the Japanese  Ministry of Education, Science  and Culture 
(02557026). 
Address correspondence  to Teizo Fujita, Department of Biochemistry, Fukushima Medical College, 
1-Hikariga-oka, Fukushima 960-12, Japan. 
Received for publication 24 July 1992. 
~l~ll~rences 
1.  Drickamer, K.  1988. Two distinct classes of carbohydrate- 
recognition  domains  in animal  lectins.f Biol. Chem. 263:9557. 
2.  Kawasaki,  N., T. Kawasaki, and I. Yamashina. 1983. Isolation 
and characterization  of  a mannan-binding  protein  from human 
1501  Matsushita  and Fujita 
serum. J. Biochem. 94:937. 
3.  Kozutsumi, Y., T. Kawasaki, and I. Yamashina. 1980. Isola- 
tion and characterization  of a mannan-binding  protein from 
rabbit serum. Biochem. Biophys. Res. Commun. 95:658. 4.  Oka, S., K. Ikeda, T. Kawasaki, and I. Yamashina. 1988. Isola- 
tion and characterization of two distinct mannan-binding pro- 
tein from rat serum. Arch. Biochem. Biophys. 260:257. 
5.  Kawasaki, N., T. Kawasaki, and I. Yamashina. 1985. Mannan- 
binding protein and conglutinin in bovine serum. J. Biochem. 
98:1309. 
6.  Ezekowitz, K.A.K, L. Day, and G.A. Herman. 1988. A human 
mannose-binding protein is an acute-phase reactant that shares 
sequence homology with other vertebrate lectins.J. ExF Med. 
167:1034. 
7.  Weis, I.W., K. Kahn, K. Fourme, K. Drickamer, and W.A. 
Hendrickson. 1991. Structure of the calcium-dependent lectin 
domain from a rat mannose-binding protein determined by 
MAD phasing. Science (Wash. IX2). 254:1608. 
8.  Kuhlman, M., K. Joiner, and R.A.B. Ezekowitz.  1989. The 
human mannose-binding protein functions as an opsonin. J. 
Exll Med. 169:1733. 
9.  Super, M., S. Thiel, J. Lu, K.J. Levinsky, and M.W. Turner. 
1989. Association  of  low levels  of  mannan-binding protein with 
a common defect of opsonisation. Lancet. //:1236. 
10.  Malhotra,  K., S. Thiel, K.B.M. Reid, and K.B. Sim. 1990. 
Human leukocyte  Clq receptor binds other soluble  protein with 
collagen domains. J. Exl~ Med. 172:955. 
11.  Ezekowitz, K.A.B., M. Kuhlman, J.E. Groopman, and R.A. 
Byru. 1989. A human serum mannose-binding protein inhibits 
in vitro infection by the human immunodeficiency virus. J. 
Exlx Med. 169:185. 
I2.  Larkin, M., R.A. Childs, T.J. Matthews, S. Thid, T. Mizuochi, 
A.M. Lawson, J.S. Savill, C. Haslett,  R. Diaz,  and T. Feizi. 
1989. Oligosaccharide-mediated interactions of the envelope 
glycoprotein gp120 of HIV-1 that are independent of CD4 rec- 
ognition.  AIDS (Phila.). 3:793. 
13.  Ikeda, K.,  T.  Sannoh,  N.  Kawasaki, T.  Kawasaki, and  I. 
Yamashina. 1987. Serum lectin with known structure activates 
complement  through  the classical pathway. J.  Biol. Chem. 
262:7451. 
14.  Kawasaki, N., T. Kawasaki, and I. Yamashina. 1989. A serum 
lectin (mannan-binding protein) has complement-dependent 
bactericidal activity. J. Biochem. 106:483. 
15.  Schweinle,  J.E., K.A.B. Ezekowitz, A.J. Tenner,  M. Kuhlman, 
and K.A. Joiner. 1989. Human mannose-binding protein acti- 
vates the alternative complement pathway and serum bacteri- 
cidal activity on a mannose-rich isolate of Salmonella. J. Clin. 
Invest. 84:1821. 
16.  Super, M., R.J. Levinsky, and M.W. Turner. 1990. The level 
of mannan-binding protein regulates the binding of comple- 
ment-derived opsonins to mannan and zymosan at low serum 
concentrations.  Clin. Extx Immunol. 79:144. 
17.  Ohta, M., M. Okada, I. Yamashina, and T. Kawasaki. 1990. 
The mechanism of carbohydrate-mediated complement acti- 
vation by the serum mannan-binding protein. J. Biol. Chem. 
265:1980. 
18.  Lu, J., S. Thiel, H. Wiedemann, K. Timpl, and K.B.M. Reid. 
1990. Binding of the pentamer/hexamer  forms of mannan- 
binding protein to zymosan activates the proenzyme Clr2Cls2 
complex, of the classical  pathway of  complement, without in- 
volvement of Clq. J. Immunol. 144:2287. 
19.  Matsushita, M., A. Takahashi, H. Hatsuse, M. Kawakami, and 
T. Fujita. 1992. Human mannose-binding protein is identical 
to a component of Re-reactive factor. Biochem. Bioplrys. Res. 
Commun. 183:645. 
20.  Sakai, K., and R.M. Stroud. 1973. Purification,  molecular  prop- 
erties,  and  activation  of C1  proesterase, Cls. J.  Immunol. 
110:1010. 
21.  Matsushita, M., and H. Okada. 1986. Alternative complement 
pathway activation by C4b deposited during classical pathway 
activation. J. Immunol. 136:2994. 
22.  Nagasawa, S., and K.M. Stroud. 1977. Cleavage  of C2 by Cls 
into the antigenicaUy  distinct fragments C2a and C2b: demon- 
stration of binding of C2b to C4b. Proc Natl. Acad. Sci. USA. 
74:2998. 
23.  Polly, M.J., and H.J. M(iller-Everhard. 1967. Enhancement of 
the hemolytic activity of the second component  of comple- 
ment by oxidation, f  Exp. Med. 126:1013. 
24.  Laemmli, U.K.  1970. Cleavage of structural  protein during 
the assembly of the head of bacteriophage T4. Nature (Lond.). 
27:680. 
25.  Matsushita, M., and H. Okada.  1989. Two forms of guinea 
pig factor B of the  alternative complement  pathway with 
different molecular weights. Mol. Immunol. 26:669. 
26.  Kusumoto, H., S. Hirosawa, J.P. Salier, F.S. Hagen,  and K. 
Kurachi. 1988. Human genes for complement components Clr 
and Cls in a close tail-to-tail arrangement. Proc. Natl. Acad. 
Sci. USA.  85:7307. 
27.  Kawakami, M., L Ihara, S. Ihara, A. Suzuki, and K. Fukui. 
1984. A group of bactericidal factors conserved by vertebrates 
for more than 300 million years. J. Immunol. 132:2578. 
28.  Ihara, I., Y. Harada, S. Ihara, and M. Kawakami. 1982. A new 
complement dependent bactericidal  factor found in nonimmune 
mouse sera: specific  binding to polysaccharide of Ra chemo- 
type Salmonella. J. Immunol. 128:1256. 
29.  Kawakami, M., I. Ihara, A. Suzuki, and Y. Harada. 1982. Prop- 
erties of  a new complement-dependent  bactericidal  factor specific 
for Ra chemotype Salmonella in sera of  conventional and germ- 
free mice.  f  Immunol. 129:2198. 
30.  Ihara, I., H. Ueda, A. Suzuki, and M. Kawakami. 1982. Phys- 
icochemical properties of  a new bactericidal factor, Ra-reactive 
factor. Biochem. Biophys. Res. Commun. 107:1185. 
31.  Ihara, S., A. Takahashi, H. Hatsuse, K. Sumitomo, K. Doi, 
and M.  Kawakami. 1991. Major component  of Ra-reactive 
factor, a complement-activating bactericidal protein, in mouse 
serum. J. Immunol. 146:1874. 
32. Ji,  Y.-H.,  M.  Matsushita,  H.  Okada,  T.  Fujita,  and  M. 
Kawakami. 1988. The C4 and C2 but not the C1 components 
of complement are responsible for the complement activation 
triggered by the Ra-reactive factor. J. Immunol. 141:4271. 
33.  Ihara, I., S. Ihara, A. Nagashima, Y.-H. Ji, and M. Kawakami. 
1988. The 28k and 70k dalton polypeptide components  of 
mouse Ra-reactive  factor are responsible for bacteriddal activity. 
Biochem. Biophys. Res. Commun. 152:636. 
34.  Gigli, I., R.R. Porter, and IL.B. Sire. 1976. The unactivated 
form of the first component of human complement, C1. Bio- 
chem. J.  157:541. 
1502  Mannose-binding  Protein-associated  Serine Protease 